{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:27:06Z","timestamp":1790728026882,"version":"4.1.0"},"reference-count":146,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T00:00:00Z","timestamp":1594771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>MicroRNAs (miRNAs) are a key gene regulator and play essential roles in several biological and pathological mechanisms in the human system. In recent years, plenty of miRNAs have been identified to be involved in the development of neurodegenerative disorders (NDDs), thus making them an attractive option for therapeutic approaches. Hence, in this review, we provide an overview of the current research of miRNA-based therapeutics for a selected set of NDDs, either for their high prevalence or lethality, such as Alzheimer\u2019s, Parkinson\u2019s, Huntington\u2019s, Amyotrophic Lateral Sclerosis, Friedreich\u2019s Ataxia, Spinal Muscular Atrophy, and Frontotemporal Dementia. We also discuss the relevant delivery techniques, pertinent outcomes, their limitations, and their potential to become a new generation of human therapeutic drugs in the near future.<\/jats:p>","DOI":"10.3390\/cells9071698","type":"journal-article","created":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T06:38:55Z","timestamp":1595313535000},"page":"1698","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":95,"title":["Current Status of microRNA-Based Therapeutic Approaches in Neurodegenerative Disorders"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5024-7261","authenticated-orcid":false,"given":"Sujay","family":"Paul","sequence":"first","affiliation":[{"name":"Tecnologico de Monterrey, School of Engineering and Sciences, Campus Queretaro, Av. Epigmenio Gonzalez, No. 500 Fracc. San Pablo, Quer\u00e9taro CP 76130, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6342-4842","authenticated-orcid":false,"given":"Luis Alberto","family":"Bravo V\u00e1zquez","sequence":"additional","affiliation":[{"name":"Tecnologico de Monterrey, School of Engineering and Sciences, Campus Queretaro, Av. Epigmenio Gonzalez, No. 500 Fracc. San Pablo, Quer\u00e9taro CP 76130, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"P\u00e9rez Uribe","sequence":"additional","affiliation":[{"name":"Tecnologico de Monterrey, School of Engineering and Sciences, Campus Queretaro, Av. Epigmenio Gonzalez, No. 500 Fracc. San Pablo, Quer\u00e9taro CP 76130, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8062-7441","authenticated-orcid":false,"given":"Paula","family":"Roxana Reyes-P\u00e9rez","sequence":"additional","affiliation":[{"name":"Tecnologico de Monterrey, School of Engineering and Sciences, Campus Queretaro, Av. Epigmenio Gonzalez, No. 500 Fracc. San Pablo, Quer\u00e9taro CP 76130, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9000-1378","authenticated-orcid":false,"given":"Ashutosh","family":"Sharma","sequence":"additional","affiliation":[{"name":"Tecnologico de Monterrey, School of Engineering and Sciences, Campus Queretaro, Av. Epigmenio Gonzalez, No. 500 Fracc. San Pablo, Quer\u00e9taro CP 76130, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,7,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1261\/rna.068692.118","article-title":"Post-transcriptional control of miRNA biogenesis","volume":"25","author":"Michlewski","year":"2019","journal-title":"RNA"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1177\/0271678X18773871","article-title":"MicroRNA-based therapeutics in central nervous system injuries","volume":"38","author":"Sun","year":"2018","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s11064-019-02917-y","article-title":"MicroRNAs and Child Neuropsychiatric Disorders: A Brief Review","volume":"45","author":"Paul","year":"2020","journal-title":"Neurochem. Res."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Bandiera, S., Cartault, F., Jannot, A.S., Hatem, E., Girard, M., Rifai, L., Loiseau, C., Munnich, A., Lyonnet, S., and Henrion-Caude, A. (2013). Genetic Variations Creating MicroRNA Target Sites in the FXN 3\u2032-UTR Affect Frataxin Expression in Friedreich Ataxia. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0054791"},{"key":"ref_5","first-page":"420","article-title":"microRNAs in Neurodegeneration: Current Findings and Potential Impacts","volume":"8","author":"Sharma","year":"2018","journal-title":"J. Alzheimer\u2019s Dis. Park."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.gendis.2019.09.009","article-title":"RISC assembly and post-transcriptional gene regulation in Hepatocellular Carcinoma","volume":"7","author":"Santhekadur","year":"2020","journal-title":"Genes Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4103\/0019-5545.58891","article-title":"What is schizophrenia: A neurodevelopmental or neurodegenerative disorder or a combination of both A critical analysis","volume":"52","author":"Gupta","year":"2010","journal-title":"Indian J. Psychiatry"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1038\/emm.2015.13","article-title":"Special issue on neurodegenerative diseases and their therapeutic approaches","volume":"47","author":"Kim","year":"2015","journal-title":"Exp. Mol. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1136\/jclinpath-2019-205952","article-title":"Molecular pathology of neurodegenerative diseases: Principles and practice","volume":"72","author":"Kovacs","year":"2019","journal-title":"J. Clin. Pathol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/978-3-319-22671-2_6","article-title":"microRNAs and Neurodegenerative Diseases","volume":"888","author":"Qiu","year":"2015","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Sharad, S., and Kapur, S. (2019). Therapeutic Implication of miRNA in Human Disease. Antisense Therapy, IntechOpen.","DOI":"10.5772\/intechopen.73736"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"68","DOI":"10.4103\/2229-3485.179431","article-title":"MicroRNA therapeutics: Discovering novel targets and developing specific therapy","volume":"7","author":"Christopher","year":"2016","journal-title":"Perspect. Clin. Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1242\/dmm.028613","article-title":"RNA metabolism in neurodegenerative disease","volume":"10","author":"Liu","year":"2017","journal-title":"DMM Dis. Model. Mech."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.4155\/fmc.15.107","article-title":"miRNA therapeutics: A new class of drugs with potential therapeutic applications in the heart","volume":"7","author":"Bernardo","year":"2015","journal-title":"Future Med. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1093\/nar\/gkw1085","article-title":"Prediction of human miRNA target genes using computationally reconstructed ancestral mammalian sequences","volume":"45","author":"Leclercq","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Bajan, S., and Hutvagner, G. (2020). RNA-Based Therapeutics: From Antisense Oligonucleotides to miRNAs. Cells, 9.","DOI":"10.3390\/cells9010137"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1517\/17460441.2015.981254","article-title":"MicroRNA in neurodegenerative drug discovery: The way forward?","volume":"10","author":"Campbell","year":"2015","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1261\/rna.054072.115","article-title":"Double-stranded microRNA mimics can induce length-and passenger strand-dependent effects in a cell type-specific manner","volume":"22","author":"Goldgraben","year":"2016","journal-title":"RNA"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"7820","DOI":"10.1038\/s41598-018-26050-y","article-title":"MicroRNAs as potential therapeutics to enhance chemosensitivity in advanced prostate cancer","volume":"8","author":"Lin","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.canlet.2017.05.025","article-title":"microRNA inhibitors: Natural and artificial sequestration of microRNA","volume":"407","author":"Tang","year":"2017","journal-title":"Cancer Lett."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1080\/15476286.2018.1445959","article-title":"Anti-miRNA oligonucleotides: A comprehensive guide for design","volume":"15","author":"Lima","year":"2018","journal-title":"RNA Biol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1261\/rna.2414110","article-title":"MicroRNA sponges: Progress and possibilities","volume":"16","author":"Ebert","year":"2010","journal-title":"RNA"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2174\/1389557515666150324123208","article-title":"MicroRNA Therapeutics: The Next Magic Bullet?","volume":"15","author":"Simonson","year":"2015","journal-title":"Mini Rev. Med. Chem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.drudis.2012.10.002","article-title":"Delivering the promise of miRNA cancer therapeutics","volume":"18","author":"Pereira","year":"2013","journal-title":"Drug Discov. Today"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"6782653","DOI":"10.1155\/2019\/6782653","article-title":"Current progress on microRNA-based gene delivery in the treatment of osteoporosis and osteoporotic fracture","volume":"2019","author":"Sun","year":"2019","journal-title":"Int. J. Endocrinol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"179","DOI":"10.4103\/2230-973X.167646","article-title":"An overview of viral and nonviral delivery systems for microRNA","volume":"5","author":"Yang","year":"2015","journal-title":"Int. J. Pharm. Investig."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Myoung, S., and Kasinski, A.L. (2019). Strategies for Safe and Targeted Delivery of MicroRNA Therapeutics. MicroRNAs in Diseases and Disorders: Emerging Therapeutic Targets, The Royal Society of Chemistry.","DOI":"10.1039\/9781788016421-00386"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1177\/1073858414521870","article-title":"Adeno-associated virus vectors and neurological gene therapy","volume":"21","author":"Ojala","year":"2015","journal-title":"Neuroscientist"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jconrel.2019.10.007","article-title":"MicroRNA delivery through nanoparticles","volume":"313","author":"Lee","year":"2019","journal-title":"J. Control. Release"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.jconrel.2013.09.015","article-title":"Progress in microRNA delivery","volume":"172","author":"Zhang","year":"2013","journal-title":"J. Control. Release"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Carter, M., and Shieh, J. (2015). Gene Delivery Strategies. Guide to Research Techniques in Neuroscience, Academic Press.","DOI":"10.1016\/B978-0-12-800511-8.00011-3"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3389\/fnmol.2016.00129","article-title":"Getting miRNA therapeutics into the target cells for neurodegenerative diseases: A mini-review","volume":"9","author":"Wen","year":"2016","journal-title":"Front. Mol. Neurosci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.addr.2014.10.031","article-title":"Recent progress in microRNA delivery for cancer therapy by non-viral synthetic vectors","volume":"81","author":"Wang","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.brainres.2014.04.005","article-title":"Oligonucleotide-based therapy for neurodegenerative diseases","volume":"1584","author":"Magen","year":"2014","journal-title":"Brain Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2174\/138920101708160517234941","article-title":"Lipid Nanoparticles to Deliver miRNA in Cancer","volume":"17","author":"Campani","year":"2016","journal-title":"Curr. Pharm. Biotechnol."},{"key":"ref_36","unstructured":"Grumezescu, A.M. (2018). Delivering miRNA modulators for cancer treatment. Drug Targeting and Stimuli Sensitive Drug Delivery Systems, William Andrew."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1177\/0022034516633189","article-title":"Characterization of regulatory extracellular vesicles from osteoclasts","volume":"95","author":"Huynh","year":"2016","journal-title":"J. Dent. Res."},{"key":"ref_38","first-page":"892","article-title":"Genetic of Alzheimer\u2019s disease: A narrative review article","volume":"44","author":"Khanahmadi","year":"2015","journal-title":"Iran. J. Public Health"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"7027380","DOI":"10.1155\/2017\/7027380","article-title":"Potential Roles of Exosomal MicroRNAs as Diagnostic Biomarkers and Therapeutic Application in Alzheimer\u2019s Disease","volume":"2017","author":"Chen","year":"2017","journal-title":"Neural Plast."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2217\/nmt.14.52","article-title":"The biomarker and therapeutic potential of miRNA in Alzheimer\u2019s disease","volume":"5","author":"Bekris","year":"2015","journal-title":"Neurodegener. Dis. Manag."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3389\/fphar.2019.00665","article-title":"MicroRNAs in Alzheimer\u2019s disease: Diagnostic markers or therapeutic agents?","volume":"10","author":"Angelucci","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e256","DOI":"10.1038\/mtna.2015.33","article-title":"Preclinical evaluation of miR-15\/107 family members as multifactorial drug targets for Alzheimer\u2019s disease","volume":"4","author":"Parsi","year":"2015","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"6721","DOI":"10.1093\/hmg\/ddv377","article-title":"MiR-132\/212 deficiency impairs tau metabolism and promotes pathological aggregation in vivo","volume":"24","author":"Smith","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.15252\/emmm.201606520","article-title":"miR-132 loss de-represses ITPKB and aggravates amyloid and TAU pathology in Alzheimer\u2019s brain","volume":"8","author":"Salta","year":"2016","journal-title":"EMBO Mol. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.toxlet.2011.11.032","article-title":"The miR-124 regulates the expression of BACE1\/\u03b2-secretase correlated with cell death in Alzheimer\u2019s disease","volume":"209","author":"Fang","year":"2012","journal-title":"Toxicol. Lett."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"110814","DOI":"10.1016\/j.exger.2019.110814","article-title":"Diagnostic value of miR-193a-3p in Alzheimer\u2019s disease and miR-193a-3p attenuates amyloid-\u03b2 induced neurotoxicity by targeting PTEN","volume":"130","author":"Cao","year":"2020","journal-title":"Exp. Gerontol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"108908","DOI":"10.1016\/j.cbi.2019.108908","article-title":"MiR-107 overexpression attenuates neurotoxicity induced by 6-hydroxydopamine both in vitro and in vivo","volume":"315","author":"Sun","year":"2020","journal-title":"Chem. Biol. Interact."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/jcp.28988","article-title":"MicroRNA-326 decreases tau phosphorylation and neuron apoptosis through inhibition of the JNK signaling pathway by targeting VAV1 in Alzheimer\u2019s disease","volume":"235","author":"He","year":"2020","journal-title":"J. Cell. Physiol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"4299","DOI":"10.1038\/emboj.2011.327","article-title":"MicroRNA-34c is a novel target to treat dementias","volume":"30","author":"Zovoilis","year":"2011","journal-title":"EMBO J."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e13125","DOI":"10.1111\/acel.13125","article-title":"Increased miR-34c mediates synaptic deficits by targeting synaptotagmin 1 through ROS-JNK-p53 pathway in Alzheimer\u2019s Disease","volume":"19","author":"Shi","year":"2020","journal-title":"Aging Cell"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"34433","DOI":"10.1038\/srep34433","article-title":"Replenishment of microRNA-188-5p restores the synaptic and cognitive deficits in 5XFAD Mouse Model of Alzheimer\u2019s Disease","volume":"6","author":"Lee","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1007\/s12035-020-01868-8","article-title":"Selected microRNAs Increase Synaptic Resilience to the Damaging Binding of the Alzheimer\u2019s Disease Amyloid Beta Oligomers","volume":"57","author":"Zolochevska","year":"2020","journal-title":"Mol. Neurobiol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Higaki, S., Muramatsu, M., Matsuda, A., Matsumoto, K., Satoh, J.I., Michikawa, M., and Niida, S. (2018). Defensive effect of microRNA-200b\/c against amyloid-beta peptide-induced toxicity in Alzheimer\u2019s disease models. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0196929"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.omtn.2020.01.010","article-title":"miRNA-31 Improves Cognition and Abolishes Amyloid-\u03b2 Pathology by Targeting APP and BACE1 in an Animal Model of Alzheimer\u2019s Disease","volume":"19","author":"Carmona","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.neurobiolaging.2010.04.034","article-title":"MicroRNA-16 targets amyloid precursor protein to potentially modulate Alzheimer\u2019s-associated pathogenesis in SAMP8 mice","volume":"33","author":"Liu","year":"2012","journal-title":"Neurobiol. Aging"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/ana.23588","article-title":"MiR-206 regulates brain-derived neurotrophic factor in Alzheimer disease model","volume":"72","author":"Lee","year":"2012","journal-title":"Ann. Neurol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"113128","DOI":"10.1016\/j.expneurol.2019.113128","article-title":"microRNA-592 blockade inhibits oxidative stress injury in Alzheimer\u2019s disease astrocytes via the KIAA0319-mediated Keap1\/Nrf2\/ARE signaling pathway","volume":"324","author":"Wu","year":"2020","journal-title":"Exp. Neurol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.bbrc.2010.12.053","article-title":"MicroRNA-101 downregulates Alzheimer\u2019s amyloid-\u03b2 precursor protein levels in human cell cultures and is differentially expressed","volume":"404","author":"Long","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nrneurol.2017.27","article-title":"Cognitive decline in Parkinson disease","volume":"13","author":"Aarsland","year":"2017","journal-title":"Nat. Rev. Neurol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/brain\/awz350","article-title":"Genetic modifiers of risk and age at onset in GBA associated Parkinson\u2019s disease and Lewy body dementia","volume":"143","author":"Blauwendraat","year":"2020","journal-title":"Brain"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1001\/jamaneurol.2018.1885","article-title":"Frequency of loss of function variants in LRRK2 in Parkinson disease","volume":"75","author":"Blauwendraat","year":"2018","journal-title":"JAMA Neurol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/hmg\/dds470","article-title":"Microrna-205 regulates the expression of parkinson\u2019s disease-related leucine-rich repeat kinase 2 protein","volume":"22","author":"Cho","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.brainres.2014.01.010","article-title":"Targeting alpha-synuclein with a microRNA-embedded silencing vector in the rat substantia nigra: Positive and negative effects","volume":"1550","author":"Khodr","year":"2014","journal-title":"Brain Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s13577-017-0187-5","article-title":"MicroRNA-30e regulates neuroinflammation in MPTP model of Parkinson\u2019s disease by targeting Nlrp3","volume":"31","author":"Li","year":"2018","journal-title":"Hum. Cell"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/bpa.12267","article-title":"MiR-124 regulates apoptosis and autophagy process in MPTP model of Parkinson\u2019s disease by targeting to bim","volume":"26","author":"Wang","year":"2016","journal-title":"Brain Pathol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e1256855","DOI":"10.1080\/23262133.2016.1256855","article-title":"Traceable microRNA-124 loaded nanoparticles as a new promising therapeutic tool for Parkinson\u2019s disease","volume":"3","author":"Saraiva","year":"2016","journal-title":"Neurogenesis"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jconrel.2016.06.005","article-title":"MicroRNA-124 loaded nanoparticles enhance brain repair in Parkinson\u2019s disease","volume":"235","author":"Saraiva","year":"2016","journal-title":"J. Control. Release"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.12659\/MSM.900218","article-title":"MicroRNA-181a regulates apoptosis and autophagy process in Parkinson\u2019s disease by inhibiting p38 mitogen-activated protein kinase (MAPK)\/c-Jun N-terminal kinases (JNK) signaling pathways","volume":"23","author":"Liu","year":"2017","journal-title":"Med. Sci. Monit."},{"key":"ref_69","first-page":"131","article-title":"Overexpression of miR-185 inhibits autophagy and apoptosis of dopaminergic neurons by regulating the AMPK\/mTOR signaling pathway in Parkinson\u2019s disease","volume":"17","author":"Wen","year":"2018","journal-title":"Mol. Med. Rep."},{"key":"ref_70","first-page":"209","article-title":"Overexpression of microRNA-183 promotes apoptosis of substantia nigra neurons via the inhibition of OSMR in a mouse model of Parkinson\u2019s disease","volume":"43","author":"Gao","year":"2019","journal-title":"Int. J. Mol. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1523\/JNEUROSCI.3900-15.2016","article-title":"MicroRNA-155 regulates alpha-synuclein-induced inflammatory responses in models of Parkinson disease","volume":"36","author":"Thome","year":"2016","journal-title":"J. Neurosci."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13024-016-0094-3","article-title":"MicroRNA-7 targets Nod-like receptor protein 3 inflammasome to modulate neuroinflammation in the pathogenesis of Parkinson\u2019s disease","volume":"11","author":"Zhou","year":"2016","journal-title":"Mol. Neurodegener."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.neulet.2018.03.037","article-title":"miR-494-3p modulates the progression of in vitro and in vivo Parkinson\u2019s disease models by targeting SIRT3","volume":"675","author":"Geng","year":"2018","journal-title":"Neurosci. Lett."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/acel.12538","article-title":"Function of the SIRT3 mitochondrial deacetylase in cellular physiology, cancer, and neurodegenerative disease","volume":"16","author":"Ansari","year":"2017","journal-title":"Aging Cell"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.neulet.2019.02.038","article-title":"miR-9-5p modulates the progression of Parkinson\u2019s disease by targeting SIRT1","volume":"701","author":"Wang","year":"2019","journal-title":"Neurosci. Lett."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s10020-018-0059-9","article-title":"Suppressed microRNA-96 inhibits iNOS expression and dopaminergic neuron apoptosis through inactivating the MAPK signaling pathway by targeting CACNG5 in mice with Parkinson\u2019s disease","volume":"24","author":"Dong","year":"2018","journal-title":"Mol. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s11011-020-00546-x","article-title":"MicroRNA-216a inhibits neuronal apoptosis in a cellular Parkinson\u2019s disease model by targeting Bax","volume":"35","author":"Yang","year":"2020","journal-title":"Metab. Brain Dis."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1750-1172-5-40","article-title":"Huntington\u2019s disease: A clinical review","volume":"5","author":"Roos","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"91","DOI":"10.31887\/DCNS.2016.18.1\/pnopoulos","article-title":"Huntington disease: A single-gene degenerative disorder of the striatum","volume":"18","author":"Nopoulos","year":"2016","journal-title":"Dialogues Clin. Neurosci."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/ene.13413","article-title":"Huntington\u2019s disease: A clinical review","volume":"25","author":"McColgan","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1038\/gt.2011.170","article-title":"Using non-coding small RNAs to develop therapies for Huntington\u2019s disease","volume":"18","author":"Zhang","year":"2011","journal-title":"Gene Ther."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1038\/mt.2011.219","article-title":"Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington\u2019s disease","volume":"19","author":"McBride","year":"2011","journal-title":"Mol. Ther."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/mt.2009.17","article-title":"Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington\u2019s disease mice","volume":"17","author":"Boudreau","year":"2009","journal-title":"Mol. Ther."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e234","DOI":"10.1038\/mtna.2015.7","article-title":"Artificial miRNAs targeting mutant huntingtin show preferential silencing in vitro and in vivo","volume":"4","author":"Monteys","year":"2015","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.bbrc.2017.05.040","article-title":"MicroRNA-27a reduces mutant hutingtin aggregation in an in vitro model of Huntington\u2019s disease","volume":"488","author":"Ban","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.ajhg.2013.05.025","article-title":"MiR-196a ameliorates phenotypes of huntington disease in cell, transgenic mouse, and induced pluripotent stem cell models","volume":"93","author":"Cheng","year":"2013","journal-title":"Am. J. Hum. Genet."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.7150\/thno.18813","article-title":"miR-196a enhances neuronal morphology through suppressing RANBP10 to provide neuroprotection in Huntington\u2019s disease","volume":"7","author":"Her","year":"2017","journal-title":"Theranostics"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.omtn.2018.01.007","article-title":"Supplemental Treatment for Huntington\u2019s Disease with miR-132 that Is Deficient in Huntington\u2019s Disease Brain","volume":"11","author":"Fukuoka","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"45","DOI":"10.14802\/jmd.16054","article-title":"Exosome-Based Delivery of miR-124 in a Huntington\u2019s Disease Model","volume":"10","author":"Lee","year":"2017","journal-title":"J. Mov. Disord."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"786","DOI":"10.4103\/1673-5374.156978","article-title":"MicroRNA-124 slows down the progression of huntington\u2019s disease by promoting neurogenesis in the striatum","volume":"10","author":"Liu","year":"2015","journal-title":"Neural Regen. Res."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Jovicic, A., Zaldivar Jolissaint, J.F., Moser, R., Silva Santos, M.D., and Luthi-Carter, R. (2013). MicroRNA-22 (miR-22) Overexpression Is Neuroprotective via General Anti-Apoptotic Effects and May also Target Specific Huntington\u2019s Disease-Related Mechanisms. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0054222"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1089\/hum.2017.199","article-title":"Artificial miRNAs Reduce Human Mutant Huntingtin Throughout the Striatum in a Transgenic Sheep Model of Huntington\u2019s Disease","volume":"29","author":"Pfister","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/gt.2017.71","article-title":"AAV5-miHTT gene therapy demonstrates suppression of mutant huntingtin aggregation and neuronal dysfunction in a rat model of Huntington\u2019s disease","volume":"24","author":"Miniarikova","year":"2017","journal-title":"Gene Ther."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1016\/j.ymthe.2018.06.021","article-title":"AAV5-miHTT Gene Therapy Demonstrates Broad Distribution and Strong Human Mutant Huntingtin Lowering in a Huntington\u2019s Disease Minipig Model","volume":"26","author":"Evers","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.omtm.2019.03.002","article-title":"AAV5-miHTT Gene Therapy Demonstrates Sustained Huntingtin Lowering and Functional Improvement in Huntington Disease Mouse Models","volume":"13","author":"Spronck","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_96","first-page":"36","article-title":"Potent and sustained huntingtin lowering via AAV5 encoding miRNA preserves striatal volume and cognitive function in a humanized mouse model of Huntington disease","volume":"48","author":"Caron","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1056\/NEJMra1603471","article-title":"Amyotrophic Lateral Sclerosis","volume":"377","author":"Brown","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1016\/S0140-6736(17)31287-4","article-title":"Amyotrophic lateral sclerosis","volume":"390","author":"Hardiman","year":"2017","journal-title":"Lancet"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"371","DOI":"10.12688\/f1000research.10476.1","article-title":"What causes amyotrophic lateral sclerosis?","volume":"6","author":"Martin","year":"2017","journal-title":"F1000Research"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.gene.2012.07.058","article-title":"A miRNA signature in leukocytes from sporadic amyotrophic lateral sclerosis","volume":"508","author":"Guida","year":"2012","journal-title":"Gene"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Ricci, C., Marzocchi, C., and Battistini, S. (2018). MicroRNAs as Biomarkers in Amyotrophic Lateral Sclerosis. Cells, 7.","DOI":"10.3390\/cells7110219"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"5609","DOI":"10.1038\/s41598-018-23139-2","article-title":"Differential expression of microRNAs and other small RNAs in muscle tissue of patients with ALS and healthy age-matched controls","volume":"8","author":"Kovanda","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_103","first-page":"5.67.1","article-title":"Rodent Models of Amyotrophic Lateral Sclerosis","volume":"69","author":"Philips","year":"2015","journal-title":"Curr. Protoc. Pharmacol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.omtn.2019.01.010","article-title":"Artificial MicroRNAs Targeting C9orf72 Can Reduce Accumulation of Intra-nuclear Transcripts in ALS and FTD Patients","volume":"14","author":"Martier","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.1093\/hmg\/ddt261","article-title":"Method for widespread microRNA-155 inhibition prolongs survival in ALS-model mice","volume":"22","author":"Koval","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s12031-014-0290-y","article-title":"Increased Expression of MicroRNA-29a in ALS Mice: Functional Analysis of Its Inhibition","volume":"53","author":"Nolan","year":"2014","journal-title":"J. Mol. Neurosci."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1365-2990.2010.01076.x","article-title":"Aberrant microRNA expression in the brains of neurodegenerative diseases: miR-29a decreased in Alzheimer disease brains targets neurone navigator 3","volume":"36","author":"Shioya","year":"2010","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/ana.24618","article-title":"Adeno-associated virus\u2013delivered artificial microRNA extends survival and delays paralysis in an amyotrophic lateral sclerosis mouse model","volume":"79","author":"Stoica","year":"2016","journal-title":"Ann. Neurol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1089\/hum.2015.122","article-title":"Therapeutic rAAVrh10 Mediated SOD1 Silencing in Adult SOD1(G93A) Mice and Nonhuman Primates","volume":"27","author":"Borel","year":"2016","journal-title":"Hum. Gene Ther."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.omtm.2019.12.007","article-title":"Intralingual and Intrapleural AAV Gene Therapy Prolongs Survival in a SOD1 ALS Mouse Model","volume":"17","author":"Keeler","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.neuroscience.2017.10.001","article-title":"Slow Intrathecal Injection of rAAVrh10 Enhances its Transduction of Spinal Cord and Therapeutic Efficacy in a Mutant SOD1 Model of ALS","volume":"365","author":"Li","year":"2017","journal-title":"Neuroscience"},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"La Rosa, P., Bertini, E.S., and Piemonte, F. (2020). The NRF2 signaling network defines clinical biomarkers and therapeutic opportunity in Friedreich\u2019s Ataxia. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21030916"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1055\/s-0037-1607279","article-title":"Differentially Regulated Cell-Free MicroRNAs in the Plasma of Friedreich\u2019s Ataxia Patients and Their Association with Disease Pathology","volume":"49","author":"Dantham","year":"2018","journal-title":"Neuropediatrics"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00415-009-1002-3","article-title":"Friedreich ataxia: The clinical picture","volume":"256","author":"Pandolfo","year":"2009","journal-title":"J. Neurol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jns.2011.01.010","article-title":"Friedreich\u2019s ataxia: Pathology, pathogenesis, and molecular genetics","volume":"303","author":"Koeppen","year":"2011","journal-title":"J. Neurol. Sci."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/brain\/104.3.589","article-title":"Friedreich\u2019s ataxia: A clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intrafamilial clustering of clinical features","volume":"104","author":"Harding","year":"1981","journal-title":"Brain"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"9369","DOI":"10.1523\/JNEUROSCI.0059-12.2012","article-title":"miR-886-3p levels are elevated in Friedreich ataxia","volume":"32","author":"Mahishi","year":"2012","journal-title":"J. Neurosci."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1080\/15384047.2018.1491505","article-title":"MicroRNA-886-3P functions as a tumor suppressor in small cell lung cancer","volume":"19","author":"Shen","year":"2018","journal-title":"Cancer Biol. Ther."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrneurol.2018.4","article-title":"Advances in therapy for spinal muscular atrophy: Promises and challenges","volume":"14","author":"Groen","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Schellino, R., Boido, M., and Vercelli, A. (2019). JNK Signaling Pathway Involvement in Spinal Cord Neuron Development and Death. Cells, 8.","DOI":"10.3390\/cells8121576"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"13111","DOI":"10.1073\/pnas.1006151107","article-title":"miRNA malfunction causes spinal motor neuron disease","volume":"107","author":"Haramati","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/jcmm.13450","article-title":"miRNA in spinal muscular atrophy pathogenesis and therapy","volume":"22","author":"Magri","year":"2018","journal-title":"J. Cell. Mol. Med."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"18312","DOI":"10.3390\/ijms160818312","article-title":"A Perturbed MicroRNA Expression Pattern Characterizes Embryonic Neural Stem Cells Derived from a Severe Mouse Model of Spinal Muscular Atrophy (SMA)","volume":"16","author":"Luchetti","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1126\/science.aad2509","article-title":"Loss of motoneuron-specific microRNA-218 causes systemic neuromuscular failure","volume":"350","author":"Amin","year":"2015","journal-title":"Science"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1093\/hmg\/ddx230","article-title":"Astrocyte-produced miR-146a as a mediator of motor neuron loss in spinal muscular atrophy","volume":"26","author":"Sison","year":"2017","journal-title":"Hum. Mol. Genet."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1093\/hmg\/ddw084","article-title":"Cell-type-specific miR-431 dysregulation in a motor neuron model of spinal muscular atrophy","volume":"25","author":"Wertz","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Valsecchi, V., Boido, M., De Amicis, E., Piras, A., and Vercelli, A. (2015). Expression of Muscle-Specific MiRNA 206 in the Progression of Disease in a Murine SMA Model. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0128560"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.ymthe.2020.01.013","article-title":"miR-206 Reduces the Severity of Motor Neuron Degeneration in the Facial Nuclei of the Brainstem in a Mouse Model of SMA","volume":"28","author":"Valsecchi","year":"2020","journal-title":"Mol. Ther."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1007\/s00415-019-09363-4","article-title":"An update on genetic frontotemporal dementia","volume":"266","author":"Greaves","year":"2019","journal-title":"J. Neurol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.ncl.2017.01.008","article-title":"Frontotemporal Dementia","volume":"35","author":"Olney","year":"2017","journal-title":"Neurol. Clin."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s40291-018-0347-7","article-title":"Alzheimer\u2019s Disease and Frontotemporal Dementia: The Current State of Genetics and Genetic Testing Since the Advent of Next-Generation Sequencing","volume":"22","author":"Goldman","year":"2018","journal-title":"Mol. Diagnosis Ther."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.expneurol.2014.06.001","article-title":"Pathogenesis\/genetics of frontotemporal dementia and how it relates to ALS","volume":"262","year":"2014","journal-title":"Exp. Neurol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2217\/nmt.14.34","article-title":"Frontotemporal dementia: Diagnosis, deficits and management","volume":"4","author":"Bott","year":"2014","journal-title":"Neurodegener. Dis. Manag."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11910-016-0707-9","article-title":"Genetics of Frontotemporal Dementia","volume":"16","author":"Olszewska","year":"2016","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3389\/fnagi.2016.00017","article-title":"Frontotemporal lobar degeneration and microRNAs","volume":"8","author":"Piscopo","year":"2016","journal-title":"Front. Aging Neurosci."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2165\/11533100-000000000-00000","article-title":"Frontotemporal lobar degeneration: Epidemiology, pathophysiology, diagnosis and management","volume":"24","author":"Rabinovici","year":"2010","journal-title":"CNS Drugs"},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Kocerha, J., Kouri, N., Baker, M., Finch, N.C., DeJesus-Hernandez, M., Gonzalez, J., Chidamparam, K., Josephs, K.A., Boeve, B.F., and Graff-Radford, N.R. (2011). Altered microRNA expression in frontotemporal lobar degeneration with TDP-43 pathology caused by progranulin mutations. BMC Genom., 12.","DOI":"10.1186\/1471-2164-12-527"},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Jiao, J., Herl, L.D., Farese, R.V., and Gao, F.-B. (2010). MicroRNA-29b Regulates the Expression Level of Human Progranulin, a Secreted Glycoprotein Implicated in Frontotemporal Dementia. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0010551"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1038\/nm.3717","article-title":"Alterations in microRNA-124 and AMPA receptors contribute to social behavioral deficits in frontotemporal dementia","volume":"20","author":"Gascon","year":"2014","journal-title":"Nat. Med."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"11213","DOI":"10.1523\/JNEUROSCI.0521-12.2012","article-title":"TMEM106B, the risk gene for frontotemporal dementia, is regulated by the microRNA-132\/212 cluster and affects progranulin pathways","volume":"32","author":"Unger","year":"2012","journal-title":"J. Neurosci."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"334","DOI":"10.2353\/ajpath.2010.091202","article-title":"miR-107 regulates granulin\/progranulin with implications for traumatic brain injury and neurodegenerative disease","volume":"177","author":"Wang","year":"2010","journal-title":"Am. J. Pathol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1093\/hmg\/ddn257","article-title":"Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia","volume":"17","author":"Rademakers","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Hashimoto, Y., Akiyama, Y., and Yuasa, Y. (2013). Multiple-to-multiple relationships between microRNAs and target genes in gastric cancer. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0062589"},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Titze-de-Almeida, S.S., Soto-S\u00e1nchez, C., Fernandez, E., Koprich, J.B., Brotchie, J.M., and Titze-de-Almeida, R. (2020). The Promise and Challenges of Developing miRNA-Based Therapeutics for Parkinson\u2019s Disease. Cells, 9.","DOI":"10.3390\/cells9040841"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"39812","DOI":"10.1038\/srep39812","article-title":"miRNA and mRNA expression analysis reveals potential sex-biased miRNA expression","volume":"7","author":"Guo","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1080\/15476286.2017.1367888","article-title":"Sources to variability in circulating human miRNA signatures","volume":"14","author":"Keller","year":"2017","journal-title":"RNA Biol."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/9\/7\/1698\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:48:51Z","timestamp":1760176131000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/9\/7\/1698"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,15]]},"references-count":146,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,7]]}},"alternative-id":["cells9071698"],"URL":"https:\/\/doi.org\/10.3390\/cells9071698","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,15]]}}}